On Tuesday, Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services, launched a federal initiative to combat what he describes as the overprescribing of psychiatric medications in the United States. Speaking at a mental health summit hosted by the Make America Healthy Again Institute, Kennedy introduced the concept of 'deprescribing,' which involves the supervised reduction or discontinuation of medications, particularly among children. He emphasized the importance of patient autonomy, informed consent, and shared decision-making in mental health care, advocating for a shift towards prevention and a holistic approach.

Recent statistics from the Centers for Disease Control and Prevention indicate that about 16.5% of U.S. adults were on psychiatric medications in 2020. As part of this initiative, the Substance Abuse and Mental Health Services Administration will produce a report analyzing national prescribing patterns. Kennedy's initiative coincides with recent FDA approvals for new psychiatric drugs, including Johnson & Johnson's Spravato nasal spray and Bristol Myers Squibb's Cobenfy, reflecting ongoing advancements in mental health treatment options. This initiative aims to reshape the mental health landscape by addressing the reliance on medications as the sole treatment option.